In line with this model the detection of SMR3A expression in tumor cells prior to therapy might serve as a surrogate marker for active ESR2 signaling during malignant progression and the presence of tumor cells with intrinsic radioresistance. The gene discussed is ESR2; the disease is neoplasm.